Glycopeptide antibiotics are actinomycete-derived antibiotics with unique tricyclic or tetracyclic heptapeptide cores that are usually glycosylated and sometimes have additional lipophilic fatty acid side chains.
Global Glycopeptide Antibiotics market is estimated to be valued at US$ 2,860.5 million in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030).
Figure 1. Global Glycopeptide Antibiotics Market Share (%) in Terms of Value, By Region, 2022
Global Glycopeptide Antibiotics Market - Drivers
The increasing cases of cancer and infectious diseases such as enterococcal infections, Hepatitis and others is expected to drive the market growth during the forecast period. For instance, according to data published in September 2022 by the Centers for Disease Control and Prevention (CDC), the number of tuberculosis cases in the year 2019 in the U.S. was 8,916.
Increasing product approvals for the treatment of infectious diseases are expected to drive the market growth during the forecast period. For instance, in July 2021, AbbVie Inc., a U.S. biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved DALVANCE for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 2,860.5 Mn |
| Historical Data for: | 2017-2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 4.2 % | 2030 Value Projection: | US$ 3,986.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Glycopeptide Antibiotics Market Share (%), By Distribution Channel, 2022
Global Glycopeptide Antibiotics Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic significantly impacted the glycopeptide antibiotics market. This included disruption in clinical trials, hurdles in patient recruitment for clinical trials, and canceled or delayed studies. However, the negative impact was gradually reduced by several strategic measures taken by governments, regulatory bodies, and market stakeholders to ensure the continuity of research and development (R&D) activities. Due to the urgent need for vaccines, diagnostics, and therapies, the clinical trials were restarted by employing social distancing techniques. Moreover, to support the clinical trials of COVID-19 vaccines and treatments, public organizations across the globe invested in research and development activities. For instance, according to an article published in BMJ Publishing Group Ltd., a U.K.-based publisher of medical journals, since January 2020, the U.K. government was found to be the largest funder of Oxford–AstraZeneca vaccine R&D, contributing £33,354,469 (US$ 36,762,962) (95.5%). Charitable funders accounted for £1,217,835 (US$ 1,342,286) (3.5%), the majority of which came from the Welcome Trust. Globally, most sites conducting clinical trials other than COVID-19 were found to experience delays in timelines. In some cases, clinical trials were found to reach a complete halt of operations, thus impacting clinical research outcomes. In March 2020, the U.S. FDA published a guidance document on the Conduct of Clinical Trials of Medical Products during the pandemic. Similar guidelines supported the recovery of the clinical trial operations and the number is expected to increase over time.
Global Glycopeptide Antibiotics Market: Restraint
The major factors that hinder growth of the global glycopeptide antibiotics market include increase in glycopeptide antibiotic resistance cases. For instance, according to Antibiotic Resistance Threats Report in the United States, 2019, Enterococcus which is Vancomycin (glycopeptide antibiotic) resistant bacteria caused 5,400 deaths in U.S. in 2019.
Global Glycopeptide Antibiotics Market: Key Players
Key players operating in the market include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.
Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.
Market Dynamics
Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients